Linkedin Instagram Youtube Facebook
Home
4.3 References

4.3 References

  1. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. New England Journal of Medicine. 2016;375(4):323-34.
  2. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New England Journal of Medicine. 2019;380(24):2295-306.
  3. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine. 2019;381(21):1995-2008.
  4. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine. 2020;383(15):1413-24.
  5. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, et al. Dapagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine. 2020;383(15):1436-46.
  6. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine. 2021;385(16):1451-61.
  7. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. New England Journal of Medicine. 2022;387(12):1089-98.
  8. EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine. 2022.
  9. Zynquista: https://www.ema.europa.eu/en/medicines/human/EPAR/zynquista (accessed 14th December 2022).
  10. National Institute for Health and Care Excellence (NICE). Sotagliflozin with insulin for treating type 1 diabetes (TA622). Available at: https://www.nice.org.uk/guidance/ta622 (Accessed 3rd January 2023).
  11. Napp Pharmaceutical Limited, 01 Jan 2021. Summary of Product Characteristics – Invokana (Canagliflozin). (Online). Updated:26 Nov 2021. Available at: https://www.medicines.org.uk/emc/product/8855/smpc (Accessed 08 December 2022).
  12. AstraZeneca, 01 Jan 2021. Summary of Product Characteristics – Forxiga (Dapagliflozin). (Online). Updated: 06 Dec 2022. Available at: https://www.medicines.org.uk/emc/product/7607/smpc (Accessed 08 December 2022).
  13. Boehringer Ingelheim, 01 Jan 2021. Summary of Product Characteristics – Jardiance (Empagliflozin). (Online). Updated Oct 2022. Available at: https://www.medicines.org.uk/emc/product/5441/smpc (Accessed 08 December 2022).
  14. Merck Sharp & Dohme (UK) Limited, 21 Mar 2018. Summary of Product Characteristics – Steglatro (Ertugliflozin). (Online). Updated 05 Apr 2022. Available at: https://www.medicines.org.uk/emc/product/10099/smpc (Accessed 08 December 2022).
Previous: 4.3 References
Next: Section 5.0